On November 15, 2025, the '6th Zhongshan Hospital Gastroenterology Academic Conference,' initiated by the Shanghai Xinxin Medical Technology Development Foundation, concluded successfully in Shanghai.

The conference closely focuses on the clinical development and academic needs in the field of digestive system diseases, bringing together top experts and physicians from across the country. Through in-depth academic discussions and sharing of clinical experiences, it promotes the exchange and mutual learning of treatment experiences, helps clinicians accurately master cutting-edge knowledge and standardized diagnostic and treatment pathways, comprehensively enhances overall clinical capabilities, drives the iterative advancement of disciplinary research and academic standards, and ultimately benefits a broad range of patients.

Schedule of the 6th Zhongshan Hospital Gastroenterology Conference

Opening remarks by Professor Shen Xizhong, Chairman of the Conference and Director of the Department of Gastroenterology, Zhongshan Hospital affiliated with Fudan University

Professor Shen Xizhong, Chairman of the Conference and Director of the Department of Gastroenterology at Zhongshan Hospital Affiliated to Fudan University, delivered the opening speech, warmly welcoming and sincerely thanking all the experts and colleagues present. He expressed hope that this meeting would help clinicians strengthen their accumulation of cutting-edge knowledge, optimize the standardization of diagnosis and treatment processes, further enhance comprehensive diagnostic and treatment capabilities, and explore directions for the high-quality development of the diagnosis and treatment of digestive system diseases.

Suzhou Sinochem Pharmaceutical Industry Co., Ltd. (hereinafter referred to as "Suzhou Sinochem Pharmaceutical") was invited to attend the meeting as a representative enterprise focusing on the digestive field. The company fully engaged with the core topics of the meeting, actively absorbing cutting-edge treatment concepts and practical

experience. Its core product, Lipofe® Policarbophil Calcium, is widely recognized for its scientifically grounded treatment philosophy in authoritative domestic and international guidelines. Leveraging its advantages as a bulk-forming laxative and its stepwise treatment principle, it provides practical support for enhancing clinical treatment capabilities, aligning closely with the meeting’s core goal of "improving comprehensive treatment abilities."

Based on diverse clinical needs, Libopef® Polycarbophil Calcium (tablets/granules) is designed with a dual formulation: tablets are suitable for routine treatment needs of general patients, while granules are specially designed for those who have difficulty swallowing, significantly improving medication adherence and reducing administration risks, thereby achieving differentiated therapeutic coverage. As a professional bulk-forming laxative (stool softener), its main component, polycarbophil calcium, decalcifies in the acidic environment of the stomach to form polycarbophil, which then absorbs water and swells in the intestines to form a hydrophilic gel. This effectively increases stool water content and volume, making stools soft and easy to pass. It can specifically relieve constipation symptoms in various scenarios, including functional constipation, irritable bowel syndrome-related constipation, constipation associated with benign anorectal diseases, and postoperative constipation. At the same time, this component is not absorbed into the bloodstream, making long-term use safer.

The launch of Libope® Plecabarb Calcium provides a safe and effective new option for the clinical treatment of constipation, and also adds a high-quality solution for physicians' diagnosis and treatment.

This conference, as an important academic exchange platform in the field of gastroenterology in Shanghai, has established an efficient communication bridge for industry development. Suzhou Zhonghua Pharmaceuticals, through deep participation in such academic activities, engages in in-depth exchanges with clinical experts to jointly explore high-quality treatment solutions for digestive system diseases. In the future, Suzhou Zhonghua

Pharmaceuticals will continue to focus on the research and development and technological breakthroughs of drugs for digestive system diseases, providing more solid scientific medical support to achieve the goals of the 'Healthy China' strategy.